Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA.

导出原文传递

翻译打印收藏纠错

作者： R,Houot ^[1] ; C,Soussain ^[2] ; H,Tilly ^[3] ; C,Haioun ^[4] ; C,Thieblemont ^[5] ; O,Casasnovas ^[6] ; K,Bouabdallah ^[7] ; F,Morschhauser ^[8] ; S,Le Gouill ^[9] ; G A,Salles ^[10] ; K,Hoang-Xuan ^[11] ; S,Choquet ^[12] ; T,Marchand ^[13] ; C,Laurent ^[14] ; C,Pangault ^[15] ; T,Lamy ^[13]

作者单位： Department of Hematology, CHU Rennes, Rennes roch.houot@chu-rennes.fr. ^[1] Department of Hematology, Centre René Huguenin, Saint-Cloud. ^[2] Department of Hematology, Centre Henri Becquerel, Rouen. ^[3] Lymphoid Malignancies Unit, CHU Henri Mondor, Créteil. ^[4] Department of Hematology, APHP, Hôpital Saint-Louis, Paris. ^[5] Department of Hematology, CHU Dijon, Dijon. ^[6] Department of Hematology, CHU Bordeaux, Bordeaux. ^[7] Department of Hematology, CHU Lille, Lille. ^[8] Department of Hematology, CHU Nantes, Nantes. ^[9] Department of Hematology, CHU Lyon-Sud, Pierre-Benite. ^[10] Departments of Neurology. ^[11] Hematology, APHP, Groupe Hospitalier Pitié-Salpêtrière, Paris. ^[12] Department of Hematology, CHU Rennes, Rennes. ^[13] Department of Pathology, Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse. ^[14] Laboratory of Hematology, CHU Rennes, Rennes, France. ^[15]